J&J Accepts Offer to Acquire Ortho-Clinical Diagnostics

Johnson and Johnson said Monday that it accepted an offer from The Carlyle Group, extended in January, to acquire Raritan, N.J.-based Ortho-Clinical Diagnostics.

The sale is part of J&J’s plan to shed low-performing businesses and focus on areas in which it is a market leader, spokesman Ernie Knewitz said.

Ortho-Clinical Diagnostics provides clinical chemistry and immunoassay tools for screening, diagnosis, monitoring and confirming heart disease, diabetes, drug abuse, prenatal health, infectious diseases, cancer and blood typing. The products are used in hospitals, laboratories and blood centers.

The deal, worth about $4 billion, is expected to close by the middle of this year. — Lena Freund

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.